WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rosacea and Ivermectin

Phase 2

Active, not recruiting

Conditions: Rosacea

Interventions: Drug: ivermectin
Device: GPSkin
Behavioral: digital interaction

First Posted Date: 2020-02-19

Last Posted Date: 2024-12-04

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 30

Registration Number: NCT04275999

Locations: 🇺🇸
Wake Forest Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Phase 2

Withdrawn

Conditions: Pyoderma Gangrenosum

Interventions: Drug: secukinumab 150 mg (2 injections per dose

First Posted Date: 2020-02-18

Last Posted Date: 2021-05-28

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04274166

Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region

Not Applicable

Withdrawn

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Device: Lara Scan
Diagnostic Test: PET/CT Scan - Pre-treatment and Post-treatment

First Posted Date: 2020-02-12

Last Posted Date: 2022-03-29

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04266470

Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency

Phase 4

Withdrawn

Conditions: Menopause Related Conditions

Interventions: Drug: Placebo oral soft chew
Drug: Quercetin

First Posted Date: 2020-02-06

Last Posted Date: 2022-10-10

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04258410

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Phase 2

Recruiting

Conditions: Nonsmall Cell Lung Cancer
Performance Status

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab paclitaxel
Other: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)
Other: QLQ-C30 Global Health/Quality of Life Questionnaire
Other: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes
Drug: Pemetrexed

First Posted Date: 2020-02-05

Last Posted Date: 2024-04-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 80

Registration Number: NCT04253964

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Return to Baseball After BFR Therapy for Shoulder Injury

Not Applicable

Withdrawn

Conditions: Musculoskeletal Injury

Interventions: Device: Blood Flow Restriction Therapy
Other: Standard physical rehabilitation

First Posted Date: 2020-01-30

Last Posted Date: 2022-05-16

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04248413

Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults

Early Phase 1

Withdrawn

Conditions: Heart Failure
Frailty Syndrome

Interventions: Biological: Allogeneic Young Plasma

First Posted Date: 2020-01-27

Last Posted Date: 2020-05-22

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04241159

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Incentives to Decrease Opioid Use - Pilot

Not Applicable

Completed

Conditions: Substance-Related Disorders
Opioid-Related Disorders
Behavior Therapy

Interventions: Behavioral: App + Inputs Contingency Management
Behavioral: App + Outcomes Contingency Management

First Posted Date: 2020-01-22

Last Posted Date: 2024-10-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 36

Registration Number: NCT04235582

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Aurora Psychiatric Hospital, Wauwatosa, Wisconsin, United States
🇺🇸
University of California - Santa Cruz, Berkeley, California, United States

Reports on Sleep Quality and Thermoregulation Among Veterans

Not Applicable

Withdrawn

Conditions: Sleep Disturbance

Interventions: Device: chilipad

First Posted Date: 2020-01-22

Last Posted Date: 2020-08-07

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04236661

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab

First Posted Date: 2020-01-18

Last Posted Date: 2022-04-21

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT04230031

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy